CLBR-001

N/A

Report date: 2025/04/18 16:08:34

Base Information

Drug NameCLBR-001
Drug Alias Nameanti-CD19 CAR T-cell therapy (Calibr/AbbVie)CLBR-001CLBR-001+SWI-019
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionB-lymphocyte antigen CD19 modulators
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsPrimary mediastinal B cell lymphomaMetastatic breast cancerSplenic marginal zone lymphoma +[14] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesCalifornia Institute For Biomedical ResearchAbbvie Inc
China Registration ClassN/A

Develop Information

Active CompaniesAbbvie IncCalifornia Institute For Biomedical Research
Inactive CompaniesN/A
Active IndicationsPrimary mediastinal B cell lymphomaMetastatic breast cancerSplenic marginal zone lymphoma +[14] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A